NewAmsterdam Pharma Company N.V.
NAMS
$36.40
-$0.07-0.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.76% | 18.07% | -36.54% | -20.20% | -46.68% |
| Total Depreciation and Amortization | 188.52% | 172.73% | 130.61% | 228.95% | 1,486.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.42% | -13.75% | 287.85% | 73.78% | 53.65% |
| Change in Net Operating Assets | -0.83% | -230.15% | -657.01% | -130.72% | -119.45% |
| Cash from Operations | 34.20% | 14.35% | -12.28% | -90.50% | -2,703.75% |
| Capital Expenditure | 69.97% | 24.63% | -2,700.00% | -414.94% | -162.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -35,961.88% | -14,727.86% | -261,766.67% | -414.94% | -162.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 128.93% | 127.67% | 7,317.37% | -19.09% | -49.58% |
| Repurchase of Common Stock | 100.00% | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -212.82% | -212.82% | -- | 82.22% | 91.11% |
| Cash from Financing | 129.83% | 128.55% | 7,300.21% | 22.36% | -37.05% |
| Foreign Exchange rate Adjustments | 4,179.07% | -5.73% | -234.64% | 257.44% | -95.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 850.98% | 570.95% | 438.86% | -37.11% | -95.64% |